Ausl della Romagna- Ravenna

Ravenna 48121

2 studies enrolling now · 3 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small-Cell Lung, Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Studies at this site

• Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
• Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — Available (expanded access)
• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC — Running, not enrolling